Now I have enough information to write the consolidated review. Let me produce it.

## Summary

This paper proposes MMFRL (Multimodal Fusion with Relational Learning for Molecular Property Prediction), a framework that pre-trains DMPNN encoders on five molecular modalities (fingerprint, SMILES, NMR_spectrum, NMR_peak, image) using a modified relational learning (MRL) objective, then fuses representations at early, intermediate, or late stages. The main contributions are: (1) a continuous relational learning metric that avoids binary positive/negative pairs, (2) a systematic comparison of three fusion stages, and (3) empirical results on 11 MoleculeNet benchmarks. Intermediate fusion achieves the best results on 7 of 11 tasks.

## Strengths

- **Systematic comparison of early, intermediate, and late fusion across 11 benchmarks.** Tables 2 and 3 provide a clean head-to-head evaluation of the three fusion strategies under identical conditions. Intermediate fusion wins on 7/11 tasks, late fusion on 2/11, giving practitioners actionable guidance about when each strategy is appropriate. The analysis of why different fusion timings succeed (e.g., intermediate fusion capturing cross-modal interactions, late fusion exploiting dominant modalities) is well-reasoned.

- **Internal experimental controls are valid.** The DMPNN backbone, unimodality pre-trained variants, and MMFRL fusion variants are all run under the same scaffold split (80/10/10, Chemprop) and the same evaluation protocol, so the comparison between "No Pre-training," "Unimodality_avg," and "MMFRL_{early/intermediate/late}" is trustworthy. The intermediate fusion model clearly outperforms the DMPNN baseline on most tasks (e.g., BBBP 95.4 vs. 91.9, ESOL RMSE 0.730 vs. 1.050, ClinTox 93.4 vs. 90.6).

- **ClinTox case demonstrates fusion recovering from negative pre-training.** On ClinTox, every individual pre-trained modality underperforms the no-pre-training baseline (average 85.0 vs. 90.6), yet MMFRL_intermediate reaches 93.4±1.1 — the best result across all methods. This honestly presented result is a genuine strength, showing that fusion can extract complementary information even when individual modalities are unhelpful.

- **Post-hoc explainability analysis provides some chemical insight.** The t-SNE visualization for ESOL (Figure 2) shows that intermediate fusion produces a smoother solubility gradient than any individual modality, and the late fusion contribution analysis for Lipo (Figure 4) reveals that SMILES and Image dominate while NMR_spectrum and Fingerprint contribute negligibly — mirroring the unimodality results in Table 1.

## Weaknesses

### Fatal
None. The internal experiments are sound and support the framework's value.

### Major

1. **Uncontrolled baseline comparisons weaken the headline SOTA claim.** The paper claims that MMFRL "significantly outperforms existing methods" (abstract, Section 4.2) and compares against AttentiveFP, GEM, Uni-Mol, InfoGraph, GraphCL, MolCLR, and GraphMVP (Tables 2–3). However, there is no statement that these baselines were re-run under the paper's scaffold split, seed settings, or hyperparameter search. The 20–30 point gap on BBBP (AttentiveFP 64.3, GEM 72.4, Uni-Mol 72.9 vs. DMPNN 91.9) is far larger than typical cross-paper variation and strongly suggests different experimental setups. This does **not** invalidate the paper's internal comparisons (MMFRL variants vs. DMPNN), but the claim of SOTA over prior published methods is not supported by controlled evidence. The paper must either re-run baselines under the same conditions or explicitly caveat that cross-paper comparisons are suggestive, not rigorous.

2. **No ablation isolates the contribution of the Modified Relational Learning (MRL) metric.** MRL is presented as a key conceptual contribution (Section 3.1, Theorem 1). Yet every experiment compares full MMFRL (MRL + multimodal fusion) against baselines with entirely different pre-training objectives (InfoNCE, mutual information, 3D alignment, etc.). There is no experiment that holds the pre-training data and backbone constant and varies only MRL vs. a standard contrastive loss (e.g., InfoNCE). The observed gains could come entirely from combining more modalities or from the fusion architecture. Without this ablation, the paper cannot substantiate its claim that MRL itself is beneficial.

### Minor

1. **Motivating example (thalidomide) does not align with the method's actual capabilities.** The introduction motivates MRL by arguing that binary contrastive loss cannot distinguish enantiomers like thalidomide, and that a continuous metric is needed. However, the MRL target similarities are computed from fixed embeddings of fingerprint, SMILES, NMR, and Image — modalities that are nearly identical for enantiomers. The method as described would not distinguish (R)- from (S)-thalidomide any better than binary contrastive learning. This disconnect between motivation and mechanism should be addressed.

2. **Apparent table error in Table 3.** The "Unimodality_avg" row in Table 3 (regression) reports values that exactly match the NMR_Peak row from Table 1 (ESOL: 0.924±0.083, FreeSolv: 1.707±0.126, Lipo: 0.587±0.021), rather than the actual cross-modality averages (0.830, 1.766, 0.586 from Table 1). This appears to be a copy-paste error that makes the reported Unimodality_avg regression numbers unreliable as a baseline.

3. **No sensitivity analysis for early fusion weights.** Early fusion uses fixed uniform weights (0.2 per modality) with no sensitivity study, no learned weights, and no justification. The conclusion that early fusion is "limited" (Section 4.3.1) may be an artifact of this arbitrary choice rather than an inherent limitation of early fusion.

4. **No statistical significance testing.** Several paired comparisons have overlapping error bars (e.g., Table 2 Tox21: all methods within ~85.4±0.9 to 85.1±0.1). Without significance tests or corrected confidence intervals, it is unclear which differences are reliable.

5. **Theorem 1 overstates a basic property.** Theorem 1 proves that the cross-entropy between a target distribution \(t\) and \(\text{softmax}(d)\) is minimized when \(\text{softmax}(d) = t\). This is a standard property of the cross-entropy loss with softmax parameterization, not a substantive theoretical result. The paper's framing ("principles of convergence," Theorem label) inflates its significance.

### Trivial
- "Unimodality_avg" in Table 2 duplicates the "Average" row from Table 1 for classification tasks, adding clutter without information.
- Minor typographical issues (e.g., "totters" instead of a standard term for graph loops, "downsteam" → "downstream").
- Table 2 caption notes "N-Gram is highly time-consuming on ToxCast" with a dash in the table — this reads as an artifact of comparing against a different experimental protocol.

## Nice-to-Haves

- An ablation comparing MRL against InfoNCE/SimCLR under the same multimodal pre-training data, backbone, and fusion strategy would directly validate the claimed contribution of the relational learning metric.
- A larger pre-training dataset (current: ~25k molecules from NMRShiftDB-2) would align with practice in the field (e.g., GROVER: 11M, MolCLR: 10M) and potentially increase the margin of improvement.
- Learnable fusion weights for early fusion, or at least a sensitivity analysis across \(w_R \in \{0, 0.2, 0.5, 1.0\}\), would strengthen the conclusion that early fusion is limited.

## Removed Points

These points are flagged to be removed, treat them with caution:

- **Missing appendix / proof omitted** — The parser strips appendix sections from all papers; the proof existed in the original submission.
- **Missing hyperparameter details (epochs, LR, batch size)** — These are nitpicks on reproducibility; the paper provides the key data, split, and backbone information. Per guidelines, trivial implementation details from the original submission are not author errors.
- **"Not yet released" / reproducibility concerns about cited references** — All models and datasets cited in the paper are assumed to exist and be released as of the review date.
- **Criticism about missing related work (GROVER, MolCLR with graph-image pairs)** — Per guidelines, missing related work citations should not be raised as weaknesses without external verification.
- **Claim that intermediate fusion lacks comparison to "concatenating features from separately pre-trained unimodal encoders"** — Intermediate fusion as implemented is precisely concatenation of unimodal encoders' features + MLP. This criticism misreads the paper.
- **Accusation that ClinTox result "weakens the narrative"** — The paper openly acknowledges this case and uses it to demonstrate fusion's value, which is honest and appropriate.

## Novel Insights

The reviews surface an interesting tension: the paper's strongest internal result — that fusion can recover from individual pre-training that *hurts* performance (ClinTox) — simultaneously makes its strongest case for the fusion framework while undercutting the claim that pre-training itself is beneficial. This suggests the paper's real contribution may be the fusion design study rather than the MRL pre-training objective. A revision that reframes the narrative around the fusion comparison and demotes the MRL novelty to a secondary finding would better align the claims with the evidence.

## Suggestions

1. **Reframe the contribution.** De-emphasize "state-of-the-art over prior methods" (which requires re-running baselines) and emphasize the controlled fusion study. The internal comparison of MMFRL variants against a re-run DMPNN backbone is already convincing.
2. **Fix the Table 3 error.** The Unimodality_avg row for regression tasks appears to incorrectly report NMR_Peak values instead of cross-modality averages.
3. **Add an MRL ablation.** Pre-train DMPNN on the same multimodal data with InfoNCE loss and compare downstream performance to MRL-pretrained models. This single experiment would validate or refute the claimed contribution.
4. **Either re-run baselines or add a disclaimer.** If re-running is infeasible, explicitly state that comparisons to prior published numbers are cross-paper and note the split/experimental differences.
5. **Add statistical testing.** A simple paired Wilcoxon signed-rank test across seeds for the DMPNN vs. MMFRL_intermediate comparison would add rigor.
6. **Replace or contextualize the thalidomide example.** Either use an example that MRL can actually solve, or explain why the continuous metric is still a step forward even for tasks the current modalities cannot distinguish.

## Score and Decision

MY FINAL SCORE: <pineapple>5.0</pineapple>
MY FINAL DECISION: <orange>Reject</orange>